Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 10, Issue 3, Pages 120
Publisher
MDPI AG
Online
2020-09-10
DOI
10.3390/jpm10030120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
- (2020) Bastien Jamet et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis
- (2019) Hanqing Li et al. ANNALS OF HEMATOLOGY
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
- (2019) Qiumei Yao et al. Frontiers in Oncology
- VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months
- (2019) Elizabeth L Courville et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
- (2019) Sini Luoma et al. ANNALS OF HEMATOLOGY
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA
- (2019) Herve Avet-Loiseau et al. Clinical Lymphoma Myeloma & Leukemia
- DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response /MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study
- (2019) Alessandro Gozzetti et al. Clinical Lymphoma Myeloma & Leukemia
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
- (2019) Hervé Avet-Loiseau et al. Clinical Lymphoma Myeloma & Leukemia
- Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
- (2019) Luzalba Sanoja-Flores et al. BLOOD
- How I treat the young patient with multiple myeloma
- (2018) Sara Gandolfi et al. BLOOD
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
- (2018) Mohamad Mohty et al. Clinical Lymphoma Myeloma & Leukemia
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA
- (2018) Giulia Biancon et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone
- (2018) Dickran Kazandjian et al. JAMA Oncology
- Utilizing next-generation sequencing in the management of multiple myeloma
- (2017) Marta Lionetti et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
- (2017) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates
- (2017) José Antonio Delgado et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
- (2017) Brian G M Durie et al. LANCET
- Monoclonal antibody therapy in multiple myeloma
- (2017) C Touzeau et al. LEUKEMIA
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
- (2017) J R Mills et al. Blood Cancer Journal
- Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
- (2017) Anna Oberle et al. HAEMATOLOGICA
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
- (2016) Artur Jurczyszyn et al. AMERICAN JOURNAL OF HEMATOLOGY
- MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia
- (2016) Irene Della Starza et al. BRITISH JOURNAL OF HAEMATOLOGY
- New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
- (2016) Ola Landgren et al. CLINICAL CANCER RESEARCH
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Differentiation stage of myeloma plasma cells: biological and clinical significance
- (2016) B Paiva et al. LEUKEMIA
- Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
- (2016) Artur Jurczyszyn et al. LEUKEMIA & LYMPHOMA
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
- (2016) Stefania Oliva et al. Oncotarget
- Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service
- (2015) Andy C. Rawstron et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
- (2015) Ola Landgren et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting
- (2015) Maria Arroz et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside
- (2015) Sham Mailankody et al. Nature Reviews Clinical Oncology
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- (2015) A M Rajan et al. Blood Cancer Journal
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
- (2014) M.-V. Mateos et al. BLOOD
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Advancements in Multiple Myeloma
- (2014) Alessandro Gozzetti et al. Frontiers in Oncology
- Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
- (2013) S. Z. Usmani et al. BLOOD
- Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study
- (2013) Joaquin Martinez-Lopez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease in Multiple Myeloma
- (2013) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
- (2013) E M Ocio et al. LEUKEMIA
- Association of response endpoints with survival outcomes in multiple myeloma
- (2013) S Lonial et al. LEUKEMIA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
- (2011) Alessandro Gozzetti et al. CANCER
- Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin
- (2010) Michela Cini et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma
- (2009) Ritu Gupta et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
- (2009) T. B. Bartel et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response
- (2008) Pilar Martínez-Sánchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses
- (2008) Michael R. Loken et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1
- (2008) R. A. Brooimans et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
- (2008) A. C. Rawstron et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now